John Strunk
Psychiatry · Dothan, ALNPI 1811983596
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,992 of the $25,732 with a category attached, or 77.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $9,134 and has fallen 54.9% since, to $4,123 in 2025. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,349 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$6K
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Tris Pharma Inc$1K
- plus $11K from 29 others
What the payments were for
- Speaking & faculty fees$4,62518%
- Travel & lodging$7433%
- Food & beverage$19,99278%
- Education$3721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$5,368
- LYBALVI$443
- Fanapt$228
- Quillichew ER$118
- Quillivant$118
- Dyanavel XR$118
- REXULTI$116
How this compares
$25,732 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 144 | $894,792 |
| RexultiBrexpiprazole | 251 | $370,420 |
| VraylarCariprazine Hcl | 209 | $323,886 |
| Austedo XrDeutetrabenazine | 20 | $216,202 |
| IngrezzaValbenazine Tosylate | 21 | $170,131 |
| Abilify MaintenaAripiprazole | 59 | $164,789 |
| LybalviOlanzapine/Samidorphan Malate | 61 | $97,453 |
| BelsomraSuvorexant | 204 | $89,807 |
| NuplazidPimavanserin Tartrate | 17 | $83,915 |
| Invega SustennaPaliperidone Palmitate | 26 | $73,836 |
| VyvanseLisdexamfetamine Dimesylate | 177 | $68,313 |
| NuedextaDextromethorphan Hbr/Quinidine | 41 | $60,083 |
| AuvelityDextromethorphan Hbr/Bupropion | 50 | $57,474 |
| CaplytaLumateperone Tosylate | 31 | $51,737 |
| AristadaAripiprazole Lauroxil | 15 | $48,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,643 | $1,110,994164 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,766 | $535,209310 claims |
| AbbVieVraylar, Linzess | $1,861 | $332,707225 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,399 | $170,13121 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,292 | $145,74376 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $471 | $99,286228 claims |
| MerckBelsomra | $322 | $89,807204 claims |
| Acadia Pharmaceuticals IncNuplazid | $77 | $83,91517 claims |
| Axsome Therapeutics, Inc.Auvelity, Sunosi | $606 | $79,52468 claims |
| Johnson & JohnsonInvega Sustenna | $17 | $73,83626 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $689 | $60,08341 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $456 | $51,73731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Dothan
- Fernando LopezDothan$18K
- Jonathan PfeiferDothan$7K
- Emmalyn Bady-McdowellDothan$5K
- Dallarie JamisonDothan$4K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.